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Hepatitis B virus (HBV) is a major health problem. [1,2] Globally more 
than 2 billion people have been infected with HBV, and according to 
World Health Organization (WHO) estimates, 257 million people 
were living with chronic HBV infection in 2015. Among them, 
60  million were from Africa.[2-4] After perinatal transmission, one 
of the major modes of transmission in Africa, up to 90% of infected 
infants develop chronic infection with the risk of cirrhosis, liver 
failure, cancer and premature death.[2,5] Main routes of transmission 
are in utero, by exposure to blood or body fluids during birth, and 
horizontally during early life. Prevention of transmission of HBV 
from mother to child and during early life is therefore an important 
public health goal.
In 1992, the WHO recommended the integration of hepatitis B 
vaccination into the national immunisation programmes of highly 
endemic countries by 1995 and all other countries by 1997.[6] The 
vaccination schedule consists of three or four doses of hepatitis B 
vaccine and administration of HBV immunoglobulins to infants born 
to hepatitis B surface antigen (HBsAg)-positive mothers. In addition, 
the WHO recommended a first dose of hepatitis B vaccine within 
24 hours of birth, especially in highly endemic countries (HBV 
prevalence >8%), with the objective of reducing the risk of early 
mother-to-child transmission.[7,8]
Hepatitis B vaccines are currently available not only in monovalent 
formulations but also in combinations that protect against HBV and 
several other diseases (e.g. diphtheria, tetanus and pertussis). Benefits 
of these combined vaccines include a reduction in the number of 
injections and the related cost, resulting in improved adherence to 
the vaccination programme. However, if immunisation against HBV 
begins at birth, only monovalent hepatitis B vaccine should be used, 
as the other antigens in combined vaccines are not approved for use 
at birth. For this reason, all combined vaccines are currently started 
6 weeks after birth.[9]
In 2007, the Democratic Republic of the Congo (DRC) adopted 
and implemented a universal infant hepatitis B immunisation 
programme consisting of administration of three doses of this 
vaccine in a combined formulation. Since 2009, it has been provided 
as an active pentavalent vaccine against diphtheria, tetanus, pertussis, 
Haemophilus influenzae type b and HBV (DTwP-Hib-HepB). The 
three doses of this vaccine are routinely administered to infants at the 
ages of 6, 10 and 14 weeks.[10]
Objectives
To evaluate the effect of hepatitis B vaccine in this combined 
formulation and to determine the rate of seroprotection in DRC, a 
country with a high prevalence of HBV.
Methodology
Population study
Blood from a convenience sample of 200 consecutive mother-child 
dyads was collected during routine postnatal consultations between 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
Immunisation after hepatitis B polyvalent  
vaccination among children in South Kivu Province, 
Democratic Republic of the Congo
T A Shindano,1,2 MD, PhD; R K Mbusa,3 MD; B M Kabamba,4 PhD; R Fiasse,2 MD, PhD; Y Horsmans,2 MD, PhD
1 Department of Internal Medicine, Faculty of Medicine, Université Catholique de Bukavu, Democratic Republic of the Congo
2 Gastroenterology Department, Cliniques Universitaires Saint-Luc, Faculty of Medicine, Université Catholique de Louvain, Brussels, Belgium
3 Department of Paediatrics, Faculty of Medicine, Université Catholique de Bukavu, Democratic Republic of the Congo
4  Virology Laboratory, Clinical Biology Department, Cliniques Universitaires Saint-Luc, Faculty of Medicine, Université Catholique de Louvain, 
Brussels, Belgium
Corresponding author: T A Shindano (tonyshinda@gmail.com)
Background. The World Health Organization recommends the integration of vaccination against hepatitis B virus (HBV) into the national 
immunisation programmes of all highly endemic countries. Protective efficacy, defined as a hepatitis B surface antibody (HBsAb) level 
≥10 mIU/mL, is ideally obtained in >90 - 95% of immunised children. The Democratic Republic of the Congo (DRC) implemented this 
recommendation in 2007 by introducing administration of hepatitis B vaccine in a combined formulation.
Objectives. To assess the rate of seroprotection in children who received hepatitis B vaccine in the DRC context.
Methods. This descriptive cross-sectional study was conducted during routine postnatal consultations at the General Hospital of Bukavu in 
South Kivu Province, DRC. A total of 200 infants aged 6 - 12 months and their mothers were consecutively enrolled. All the infants received 
the three-dose regimen of hepatitis B vaccine 6, 10 and 14 weeks after birth. The mothers were tested for hepatitis B surface antigen and 
HIV, while HBsAb levels were measured in the infants to determine immune response.
Results. Seroprotection was achieved in 84.5% of the infants. No maternal (age, parity, duration of pregnancy, HIV and HBV status) or 
infant (sex, weight at birth) factors were found to be associated with absence of immunological response.
Conclusions. The study demonstrated that the rate of seroprotection in the current vaccination programme against HBV in DRC was lower 
than desirable but comparable to rates reported in some other African countries. Further studies are needed to assess this finding and to 
evaluate ways to optimise the seroprotection rate.
S Afr Med J 2019;109(5):319-322. DOI:10.7196/SAMJ.2019.v109i5.12819
320       May 2019, Vol. 109, No. 5
RESEARCH
the 6th and 12th month of life at the General Hospital of Bukavu 
during 2014.
Data recorded included pregnancy information, maternal and 
infant characteristics and laboratory results (Table 1). Some of 
these variables were chosen because they have been associated 
with variations in response rates following hepatitis B vaccine 
administration.[11] In our study, mothers and infants were 
consecutively enrolled during routine visits for the immunisation 
schedule.[10] We included only infants who had received all three 
injections of hepatitis B vaccine according to their immunisation 
card. Infants who had not yet received the third dose were excluded. 
Current immunisation schedule for children in DRC[10] 
• At birth: BCG (tuberculosis), oral polio vaccine (OPV) dose 0
• At 6 weeks: OPV dose 1 and DTwP-Hib-HepB dose 1
• At 10 weeks: OPV dose 2 and DTwP-Hib-HepB dose 2
• At 14 weeks: OPV 3 and DTwP-Hib-HepB dose 3.
During the vaccination programme, anthropometric parameters of 
infants are monitored monthly up to 9 months.
Ethical considerations
The study design was approved by the Ethics Committee 
of the Catholic University of Bukavu, DRC (ref. no. UCB/CIE/
NC/03B/2014). Informed consent was obtained from all mothers 
before blood samples were collected.
Serological analyses
Samples from the mothers were analysed using reagents Determine 
HBV HBsAg (Inverness Medical Japan Ltd, Japan) for HBV and 
Determine HIV 1/2 (Abbott Diagnostics, USA) for HIV. The results 
were classified as positive or negative according to the manufacturers’ 
instructions. Subjects who were positive for HBsAg and HIV were 
considered to be carriers of both viruses. Determination of immune 
response in the infants was performed with a quantitative test 
(MONOLISA anti-HBs EIA; Bio-Rad Laboratories, USA) in the first 
122 samples and with a qualitative reagent (HBs antibodies ELISA 
test; Autobio Diagnostics, China) in the last 78 samples for economic 
reasons and because the former test was no longer available. The 
qualitative test consisted of an immunochromatographic assay in 
which results are interpreted by visual observation.
An inter-laboratory comparison was undertaken to guarantee 
the quality of laboratory results by exchanging 30 maternal samples 
with the laboratory at St Luc Hospital, Brussels, Belgium, in which 
serological tests were performed using the cobas 6000 analyser series 
(Roche, Switzerland).
Analysis of the immune response
For quantitative tests, a level of hepatitis B surface antibody (HBsAb) 
≥10 mIU/mL was considered a good immunological response 
according to the WHO criteria.[4] According to the qualitative 
test’s instructions, positive tests were considered as responders and 
negative tests as non-responders.
Statistical analysis
Results were expressed as means (standard deviations (SDs)). 
Bivariate analyses comparing two subgroups of infants, responders 
and non-responders, in terms of sociodemographic characteristics 
and associated clinical factors were performed using Student’s t-test. 
Differences between qualitative data were evaluated using the χ2 test. 
Statistical significance was set at p<0.05. Analyses were performed 
using Statistical Package for Social Sciences (SPSS) software version 
17.0 (IBM, USA).
Results
A total of 200 consecutive infants who had received the three 
doses of hepatitis B vaccine were screened for immune response to 
vaccination. Their mothers’ characteristics are set out in Table  2. 
The mean (SD) age of the mothers was 29.3 (6) years and that of 
the infants 9.1 (2.4) months. Of the mothers, 97% had normal 
term pregnancies and 93% normal deliveries. No mother reported 
having been vaccinated against HBV, while the seroprevalences of 
HIV and HBsAg were 2% and 3%, respectively. The inter-laboratory 
comparison of these tests showed identical results between the two 
laboratories.
Of the infants, 19/122 in the group tested with the quantitative kit 
had an HBsAb level <10 mIU/mL and 12/78 were negative with the 
qualitative test, giving a total of 31 non-responders (15.5%) (Table 3).
Table 3 also outlines the maternal and infant characteristics in 
the responders and non-responders. Factors such as maternal age, 
gestational age, parity and maternal HBsAg/HIV status were not 
found to significantly affect HBsAb levels in infants receiving the 
three doses of hepatitis B vaccine.
No statistically significant differences in sex or infant’s weight at 
birth were observed between responders and non-responders.
Discussion
We present the immunological response observed after universal 
hepatitis B pentavalent vaccination performed at the age of 6, 10 and 
14 weeks in the DRC. Our 15.5% rate of non-response seems high 
compared with rates of <10% in studies of infants of similar age.[12-16]
Very few studies are available on the efficacy of hepatitis B 
vaccination in sub-Saharan Africa. In these studies, the first dose 
of vaccine was given after 4 weeks of age, and not at birth as 
recommended by the WHO. Nevertheless, our rate of seroprotection 
is lower than those found in previous studies in Gambia and South 
Africa (SA), which exceed 90%.[17,18] It is, however, higher than the 
rate of 80% found in a similar study in Ivory Coast.[19] It should 
be noted that in the SA study the investigators suggested that the 
seroprotection rate of 93% could be due to a highly immunogenic 
Table 1. Characteristics of mothers and infants analysed in the study
Mothers Infants
Sociodemographic variables
Medical history (parity, vaccine status)
Characteristics of pregnancy*
Educational status
Serological status (HIV, HBsAg)
Characteristics of delivery
Gender
Number of vaccine doses
Weight at birth
Serological status (HBsAb)
HBsAg = hepatitis B surface antigen; HBsAb = hepatitis B surface antibody.
*‘Term’ was defined as gestational age between 36 and 41 weeks, ‘prematurity’ as gestational age <36 weeks, and post-term pregnancy as gestational age >41 weeks.
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vaccine and a decline in HBeAg seroprevalence as a consequence of 
several years of vaccination.[17]
In contrast to other reports, our study did not identify any maternal 
or intrinsic infant conditions associated with low immunological 
response. The mechanism of non-response to hepatitis B immuni-
sation is still unknown, but factors associated with a low immune 
response rate are type of vaccine, age, male gender, obesity and 
smoking in healthy adults, and delayed administration, preterm 
birth, low birth weight and immunodeficiency in infants. [20,21] 
In our patients, no statistically significant differences in these 
variables were observed between the responders and the non-
responders. Nevertheless, it must be noted that HBsAg and HBV 
DNA had not been tested before or at the time of hepatitis B vaccine 
administration. The possibility of an association between a certain 
type of HLA and impaired response has been suggested.[22,23] Liu et 
al.[24] found that non-response to hepatitis B vaccination in healthy 
Chinese individuals was associated with HLA B54. In Taiwan, 
Hsu et al.[25] reported that absence of response or low response 
was associated with over-expression of HLA-DR14-DR52. The 
possibility that our low response rate was due to intrinsic factors such 
as individual characteristics of our study population or malnutrition, 
which has been reported to impair response to vaccine,[8] cannot 
be excluded. Several years of war in our investigation area (South 
Kivu Province) had had numerous socioeconomic consequences, 
including malnutrition in children.
Sub-Saharan countries represent a part of the world where 
hepatitis remains endemic and transmission frequently occurs in 
utero, during delivery or during the first years of life. Childhood 
immunisation therefore represents one of the goals of prevention 
of early-life transmission with its frequent chronic complications 
such as cirrhosis and hepatocellular carcinoma.[1,3] Many studies 
have demonstrated a dramatic reduction in the incidences of 
HBV infection and associated complications as a result of the 
programme of childhood immunisation.[6,20,21,26-29] For example, 
in Southern Italy, previously considered an area of very high 
endemicity, the prevalence of HBsAg declined from 13.4% to 0.9% 
after 20 years of implementation of the vaccination programme. [20] 
Immunisation of all infants is therefore one of the WHO’s 
recommendations in the fight against HBV worldwide. Although 
these recommendations are based on the slight potential advantage 
in reduction of early transmission following a birth dose of vaccine, 
implementation of a birth dose is not always feasible in low-income 
countries for logistical and economic reasons.[8,18,30,31] In fact, only 
immunisation programmes with combined vaccines are currently 
sponsored by the WHO, and the monovalent vaccines (the only 
ones approved for use at birth) are not purchased by many African 
governments.[32] Only a few African countries have a hepatitis B 
vaccination programme with a birth dose (Nigeria, Gambia, Cape 
Verde), even if the first dose is not always given within 24 hours of 
birth as recommended, mainly for logistical and cultural reasons. [8] 
It must, however, be noted that no substantial difference in the 
response rate was reported in some studies comparing the immune 
response to hepatitis B vaccination given at birth or 4 or 6 weeks 
after delivery.[11,19,33,34]
Study limitations
Some limitations of this first study on HBV prevention in the DRC 
should be mentioned. These include the small size of our sample and 
the cross-sectional nature of the study. The latter in particular did not 
allow determination of middle/long-term protection. A prospective 
study could have identified the real rate of long-term protection, 
including slow responders. HBV DNA levels in the infants were not 
tested to identify occult HBV infection, and we did not determine 
maternal HBeAg/HBV DNA status. These factors should be taken 
into consideration when interpreting our findings. The relatively high 
rate of non-response in our study could in fact be related to some 
children having been infected prior to vaccination.[35] The switching 
from a quantitative to a qualitative anti-HBs test could also have 
affected our results, especially when interpreting borderline results 
with the qualitative test.





21 - 30 107 (53.5)




 2 - 5 191 (95.5)
Grand multipara (≥6) 5 (2.5)
Level of education
No school 1 (0.5)
Primary school 43 (21.5)
Secondary school 110 (55.0)
Post-secondary school 46 (23.0)







Age (years), mean (SD) (95% CI) 29.3 (6) (26.3 - 30.9) 29.3 (5) (27.4 - 32.4) 29 (3.3) (26.7 - 31.3) 0.921
Parity, mean (SD) (95% CI) 3.4 (0.8) (3.33 - 3.55) 3.5 (0.5) (2.96 - 3.87) 3.38 (1.6) (3.34 - 3.57) 0.841
Duration of pregnancy (weeks), mean (SD) (95% CI) 37.9 (1.3) (37.7 - 38.0)  38 (1.5) (37.8 - 38.2) 37 (1.3) (36.6 - 37.5) 0.673
HIV-positive, n (%) 4 (2.0) 3 (1.8) 1 (3.2) 0.595
HBsAg-positive, n (%) 6 (3.0) 4 (2.4) 2 (6.4) 0.220
Infant characteristics
Gender (F/M), n 107/93  90/ 79 17/ 14 0.870
Birth weight (g), mean (SD) (95% CI) 3.3 (0.4) (3.23 - 3.36) 3.3 (0.5) (3.26 - 3.39) 3.2 (0.3) (3.04 - 3.27) 0.546
SD = standard deviation; CI = confidence interval; HBsAg = hepatitis B surface antigen; F = female; M = male.
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Conclusions
The study demonstrated that the rate of seroprotection after three 
doses of hepatitis B vaccine in Congolese infants is lower than 
desirable (>90%), but comparable to some data from other African 
countries with similar socioeconomic conditions. Further studies are 
needed to assess this finding and to evaluate ways to optimise the rate 
of seroprotection.
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